nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—skin cancer—peripheral nervous system neoplasm	0.545	1	CtDrD
Vemurafenib—ABCC1—Dactinomycin—peripheral nervous system neoplasm	0.0391	0.126	CbGbCtD
Vemurafenib—ABCG2—Topotecan—peripheral nervous system neoplasm	0.0377	0.121	CbGbCtD
Vemurafenib—ABCC1—Epirubicin—peripheral nervous system neoplasm	0.0283	0.0911	CbGbCtD
Vemurafenib—ABCG2—Dactinomycin—peripheral nervous system neoplasm	0.0262	0.0842	CbGbCtD
Vemurafenib—ABCC1—Vincristine—peripheral nervous system neoplasm	0.0241	0.0775	CbGbCtD
Vemurafenib—ABCC1—Etoposide—peripheral nervous system neoplasm	0.0221	0.071	CbGbCtD
Vemurafenib—ABCG2—Vincristine—peripheral nervous system neoplasm	0.0161	0.0519	CbGbCtD
Vemurafenib—CYP1A2—Alitretinoin—peripheral nervous system neoplasm	0.0156	0.0501	CbGbCtD
Vemurafenib—ABCC1—Doxorubicin—peripheral nervous system neoplasm	0.015	0.0484	CbGbCtD
Vemurafenib—ABCG2—Cisplatin—peripheral nervous system neoplasm	0.015	0.0484	CbGbCtD
Vemurafenib—ABCG2—Etoposide—peripheral nervous system neoplasm	0.0148	0.0475	CbGbCtD
Vemurafenib—CYP1A2—Dacarbazine—peripheral nervous system neoplasm	0.0124	0.0401	CbGbCtD
Vemurafenib—ABCG2—Doxorubicin—peripheral nervous system neoplasm	0.0101	0.0324	CbGbCtD
Vemurafenib—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.00815	0.0262	CbGbCtD
Vemurafenib—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.00758	0.0244	CbGbCtD
Vemurafenib—CYP1A2—Etoposide—peripheral nervous system neoplasm	0.00609	0.0196	CbGbCtD
Vemurafenib—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.00348	0.0112	CbGbCtD
Vemurafenib—CYP2D6—Doxorubicin—peripheral nervous system neoplasm	0.00342	0.011	CbGbCtD
Vemurafenib—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00319	0.0103	CbGbCtD
Vemurafenib—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00218	0.007	CbGbCtD
Vemurafenib—Neoplasm—Epirubicin—peripheral nervous system neoplasm	0.000138	0.00169	CcSEcCtD
Vemurafenib—Mediastinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000134	0.00165	CcSEcCtD
Vemurafenib—Infection—Dactinomycin—peripheral nervous system neoplasm	0.000133	0.00163	CcSEcCtD
Vemurafenib—Cough—Alitretinoin—peripheral nervous system neoplasm	0.000133	0.00163	CcSEcCtD
Vemurafenib—Alopecia—Cisplatin—peripheral nervous system neoplasm	0.000132	0.00162	CcSEcCtD
Vemurafenib—Body temperature increased—Topotecan—peripheral nervous system neoplasm	0.00013	0.0016	CcSEcCtD
Vemurafenib—Erythema—Cisplatin—peripheral nervous system neoplasm	0.00013	0.00159	CcSEcCtD
Vemurafenib—Malnutrition—Cisplatin—peripheral nervous system neoplasm	0.00013	0.00159	CcSEcCtD
Vemurafenib—Myalgia—Alitretinoin—peripheral nervous system neoplasm	0.000129	0.00159	CcSEcCtD
Vemurafenib—Arthralgia—Alitretinoin—peripheral nervous system neoplasm	0.000129	0.00159	CcSEcCtD
Vemurafenib—Body temperature increased—Tretinoin—peripheral nervous system neoplasm	0.000129	0.00159	CcSEcCtD
Vemurafenib—Body temperature increased—Isotretinoin—peripheral nervous system neoplasm	0.000129	0.00159	CcSEcCtD
Vemurafenib—Erythema multiforme—Etoposide—peripheral nervous system neoplasm	0.000129	0.00158	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Alitretinoin—peripheral nervous system neoplasm	0.000129	0.00158	CcSEcCtD
Vemurafenib—Rash maculo-papular—Doxorubicin—peripheral nervous system neoplasm	0.000128	0.00157	CcSEcCtD
Vemurafenib—Eye disorder—Etoposide—peripheral nervous system neoplasm	0.000127	0.00157	CcSEcCtD
Vemurafenib—Neoplasm—Doxorubicin—peripheral nervous system neoplasm	0.000127	0.00156	CcSEcCtD
Vemurafenib—Cardiac disorder—Etoposide—peripheral nervous system neoplasm	0.000127	0.00155	CcSEcCtD
Vemurafenib—Photosensitivity—Epirubicin—peripheral nervous system neoplasm	0.000126	0.00155	CcSEcCtD
Vemurafenib—Myalgia—Vincristine—peripheral nervous system neoplasm	0.000125	0.00153	CcSEcCtD
Vemurafenib—Anaphylactic shock—Alitretinoin—peripheral nervous system neoplasm	0.000124	0.00152	CcSEcCtD
Vemurafenib—Angiopathy—Etoposide—peripheral nervous system neoplasm	0.000124	0.00152	CcSEcCtD
Vemurafenib—Infection—Alitretinoin—peripheral nervous system neoplasm	0.000123	0.00151	CcSEcCtD
Vemurafenib—Mediastinal disorder—Etoposide—peripheral nervous system neoplasm	0.000123	0.00151	CcSEcCtD
Vemurafenib—Chills—Etoposide—peripheral nervous system neoplasm	0.000122	0.0015	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Dactinomycin—peripheral nervous system neoplasm	0.000122	0.0015	CcSEcCtD
Vemurafenib—Nervous system disorder—Alitretinoin—peripheral nervous system neoplasm	0.000122	0.00149	CcSEcCtD
Vemurafenib—Hypersensitivity—Topotecan—peripheral nervous system neoplasm	0.000122	0.00149	CcSEcCtD
Vemurafenib—Hypersensitivity—Tretinoin—peripheral nervous system neoplasm	0.000121	0.00148	CcSEcCtD
Vemurafenib—Hypersensitivity—Isotretinoin—peripheral nervous system neoplasm	0.000121	0.00148	CcSEcCtD
Vemurafenib—Skin disorder—Alitretinoin—peripheral nervous system neoplasm	0.000121	0.00148	CcSEcCtD
Vemurafenib—Alopecia—Etoposide—peripheral nervous system neoplasm	0.00012	0.00148	CcSEcCtD
Vemurafenib—Anaphylactic shock—Vincristine—peripheral nervous system neoplasm	0.00012	0.00147	CcSEcCtD
Vemurafenib—Hypersensitivity—Melphalan—peripheral nervous system neoplasm	0.000119	0.00146	CcSEcCtD
Vemurafenib—Infection—Vincristine—peripheral nervous system neoplasm	0.000119	0.00146	CcSEcCtD
Vemurafenib—Asthenia—Topotecan—peripheral nervous system neoplasm	0.000118	0.00145	CcSEcCtD
Vemurafenib—Asthenia—Tretinoin—peripheral nervous system neoplasm	0.000117	0.00144	CcSEcCtD
Vemurafenib—Asthenia—Isotretinoin—peripheral nervous system neoplasm	0.000117	0.00144	CcSEcCtD
Vemurafenib—Nervous system disorder—Vincristine—peripheral nervous system neoplasm	0.000117	0.00144	CcSEcCtD
Vemurafenib—Pruritus—Topotecan—peripheral nervous system neoplasm	0.000117	0.00143	CcSEcCtD
Vemurafenib—Photosensitivity—Doxorubicin—peripheral nervous system neoplasm	0.000116	0.00143	CcSEcCtD
Vemurafenib—Decreased appetite—Dactinomycin—peripheral nervous system neoplasm	0.000116	0.00143	CcSEcCtD
Vemurafenib—Dysgeusia—Etoposide—peripheral nervous system neoplasm	0.000116	0.00143	CcSEcCtD
Vemurafenib—Asthenia—Melphalan—peripheral nervous system neoplasm	0.000116	0.00142	CcSEcCtD
Vemurafenib—Hypotension—Alitretinoin—peripheral nervous system neoplasm	0.000116	0.00142	CcSEcCtD
Vemurafenib—Pruritus—Tretinoin—peripheral nervous system neoplasm	0.000116	0.00142	CcSEcCtD
Vemurafenib—Pruritus—Isotretinoin—peripheral nervous system neoplasm	0.000116	0.00142	CcSEcCtD
Vemurafenib—Fatigue—Dactinomycin—peripheral nervous system neoplasm	0.000115	0.00142	CcSEcCtD
Vemurafenib—Back pain—Etoposide—peripheral nervous system neoplasm	0.000115	0.00141	CcSEcCtD
Vemurafenib—Pruritus—Melphalan—peripheral nervous system neoplasm	0.000114	0.0014	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Alitretinoin—peripheral nervous system neoplasm	0.000113	0.00139	CcSEcCtD
Vemurafenib—Diarrhoea—Topotecan—peripheral nervous system neoplasm	0.000113	0.00139	CcSEcCtD
Vemurafenib—Diarrhoea—Tretinoin—peripheral nervous system neoplasm	0.000112	0.00138	CcSEcCtD
Vemurafenib—Diarrhoea—Isotretinoin—peripheral nervous system neoplasm	0.000112	0.00138	CcSEcCtD
Vemurafenib—Hypotension—Vincristine—peripheral nervous system neoplasm	0.000112	0.00137	CcSEcCtD
Vemurafenib—Diarrhoea—Melphalan—peripheral nervous system neoplasm	0.000111	0.00136	CcSEcCtD
Vemurafenib—Pain in extremity—Epirubicin—peripheral nervous system neoplasm	0.00011	0.00136	CcSEcCtD
Vemurafenib—Myalgia—Cisplatin—peripheral nervous system neoplasm	0.00011	0.00135	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—peripheral nervous system neoplasm	0.00011	0.00135	CcSEcCtD
Vemurafenib—Dizziness—Topotecan—peripheral nervous system neoplasm	0.000109	0.00134	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Vincristine—peripheral nervous system neoplasm	0.000109	0.00134	CcSEcCtD
Vemurafenib—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.000108	0.00133	CcSEcCtD
Vemurafenib—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.000108	0.00133	CcSEcCtD
Vemurafenib—Decreased appetite—Alitretinoin—peripheral nervous system neoplasm	0.000108	0.00133	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.000107	0.00132	CcSEcCtD
Vemurafenib—Fatigue—Alitretinoin—peripheral nervous system neoplasm	0.000107	0.00131	CcSEcCtD
Vemurafenib—Constipation—Alitretinoin—peripheral nervous system neoplasm	0.000106	0.0013	CcSEcCtD
Vemurafenib—Body temperature increased—Dactinomycin—peripheral nervous system neoplasm	0.000106	0.0013	CcSEcCtD
Vemurafenib—Anaphylactic shock—Cisplatin—peripheral nervous system neoplasm	0.000106	0.0013	CcSEcCtD
Vemurafenib—Infection—Cisplatin—peripheral nervous system neoplasm	0.000105	0.00129	CcSEcCtD
Vemurafenib—Vomiting—Topotecan—peripheral nervous system neoplasm	0.000105	0.00129	CcSEcCtD
Vemurafenib—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.000104	0.00128	CcSEcCtD
Vemurafenib—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.000104	0.00128	CcSEcCtD
Vemurafenib—Rash—Topotecan—peripheral nervous system neoplasm	0.000104	0.00128	CcSEcCtD
Vemurafenib—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.000104	0.00128	CcSEcCtD
Vemurafenib—Decreased appetite—Vincristine—peripheral nervous system neoplasm	0.000104	0.00128	CcSEcCtD
Vemurafenib—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.000104	0.00127	CcSEcCtD
Vemurafenib—Cough—Etoposide—peripheral nervous system neoplasm	0.000104	0.00127	CcSEcCtD
Vemurafenib—Headache—Topotecan—peripheral nervous system neoplasm	0.000103	0.00127	CcSEcCtD
Vemurafenib—Rash—Tretinoin—peripheral nervous system neoplasm	0.000103	0.00127	CcSEcCtD
Vemurafenib—Rash—Isotretinoin—peripheral nervous system neoplasm	0.000103	0.00127	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.000103	0.00127	CcSEcCtD
Vemurafenib—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000103	0.00127	CcSEcCtD
Vemurafenib—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000103	0.00127	CcSEcCtD
Vemurafenib—Fatigue—Vincristine—peripheral nervous system neoplasm	0.000103	0.00127	CcSEcCtD
Vemurafenib—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000103	0.00126	CcSEcCtD
Vemurafenib—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.000103	0.00126	CcSEcCtD
Vemurafenib—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000103	0.00126	CcSEcCtD
Vemurafenib—Headache—Tretinoin—peripheral nervous system neoplasm	0.000103	0.00126	CcSEcCtD
Vemurafenib—Constipation—Vincristine—peripheral nervous system neoplasm	0.000102	0.00126	CcSEcCtD
Vemurafenib—Pain in extremity—Doxorubicin—peripheral nervous system neoplasm	0.000102	0.00126	CcSEcCtD
Vemurafenib—Rash—Melphalan—peripheral nervous system neoplasm	0.000102	0.00125	CcSEcCtD
Vemurafenib—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000102	0.00125	CcSEcCtD
Vemurafenib—Dry skin—Epirubicin—peripheral nervous system neoplasm	0.000101	0.00124	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.0001	0.00123	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Epirubicin—peripheral nervous system neoplasm	9.95e-05	0.00122	CcSEcCtD
Vemurafenib—Hypotension—Cisplatin—peripheral nervous system neoplasm	9.88e-05	0.00121	CcSEcCtD
Vemurafenib—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	9.86e-05	0.00121	CcSEcCtD
Vemurafenib—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	9.81e-05	0.00121	CcSEcCtD
Vemurafenib—Nausea—Topotecan—peripheral nervous system neoplasm	9.8e-05	0.0012	CcSEcCtD
Vemurafenib—Nausea—Tretinoin—peripheral nervous system neoplasm	9.73e-05	0.00119	CcSEcCtD
Vemurafenib—Nausea—Isotretinoin—peripheral nervous system neoplasm	9.73e-05	0.00119	CcSEcCtD
Vemurafenib—Anaphylactic shock—Etoposide—peripheral nervous system neoplasm	9.69e-05	0.00119	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	9.63e-05	0.00118	CcSEcCtD
Vemurafenib—Infection—Etoposide—peripheral nervous system neoplasm	9.62e-05	0.00118	CcSEcCtD
Vemurafenib—Asthenia—Dactinomycin—peripheral nervous system neoplasm	9.6e-05	0.00118	CcSEcCtD
Vemurafenib—Nausea—Melphalan—peripheral nervous system neoplasm	9.6e-05	0.00118	CcSEcCtD
Vemurafenib—Eosinophilia—Epirubicin—peripheral nervous system neoplasm	9.45e-05	0.00116	CcSEcCtD
Vemurafenib—Body temperature increased—Vincristine—peripheral nervous system neoplasm	9.45e-05	0.00116	CcSEcCtD
Vemurafenib—Skin disorder—Etoposide—peripheral nervous system neoplasm	9.41e-05	0.00116	CcSEcCtD
Vemurafenib—Dry skin—Doxorubicin—peripheral nervous system neoplasm	9.37e-05	0.00115	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Doxorubicin—peripheral nervous system neoplasm	9.2e-05	0.00113	CcSEcCtD
Vemurafenib—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	9.19e-05	0.00113	CcSEcCtD
Vemurafenib—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	9.16e-05	0.00112	CcSEcCtD
Vemurafenib—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	9.14e-05	0.00112	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	9.13e-05	0.00112	CcSEcCtD
Vemurafenib—Hypotension—Etoposide—peripheral nervous system neoplasm	9.05e-05	0.00111	CcSEcCtD
Vemurafenib—Asthenia—Alitretinoin—peripheral nervous system neoplasm	8.9e-05	0.00109	CcSEcCtD
Vemurafenib—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	8.81e-05	0.00108	CcSEcCtD
Vemurafenib—Pruritus—Alitretinoin—peripheral nervous system neoplasm	8.78e-05	0.00108	CcSEcCtD
Vemurafenib—Eosinophilia—Doxorubicin—peripheral nervous system neoplasm	8.75e-05	0.00107	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Epirubicin—peripheral nervous system neoplasm	8.72e-05	0.00107	CcSEcCtD
Vemurafenib—Weight decreased—Epirubicin—peripheral nervous system neoplasm	8.64e-05	0.00106	CcSEcCtD
Vemurafenib—Asthenia—Vincristine—peripheral nervous system neoplasm	8.58e-05	0.00105	CcSEcCtD
Vemurafenib—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	8.51e-05	0.00105	CcSEcCtD
Vemurafenib—Infestation—Epirubicin—peripheral nervous system neoplasm	8.51e-05	0.00105	CcSEcCtD
Vemurafenib—Vomiting—Dactinomycin—peripheral nervous system neoplasm	8.51e-05	0.00105	CcSEcCtD
Vemurafenib—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	8.49e-05	0.00104	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	8.44e-05	0.00104	CcSEcCtD
Vemurafenib—Rash—Dactinomycin—peripheral nervous system neoplasm	8.44e-05	0.00104	CcSEcCtD
Vemurafenib—Decreased appetite—Etoposide—peripheral nervous system neoplasm	8.42e-05	0.00103	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	8.36e-05	0.00103	CcSEcCtD
Vemurafenib—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	8.36e-05	0.00103	CcSEcCtD
Vemurafenib—Fatigue—Etoposide—peripheral nervous system neoplasm	8.35e-05	0.00103	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	8.35e-05	0.00103	CcSEcCtD
Vemurafenib—Constipation—Etoposide—peripheral nervous system neoplasm	8.28e-05	0.00102	CcSEcCtD
Vemurafenib—Dizziness—Alitretinoin—peripheral nervous system neoplasm	8.21e-05	0.00101	CcSEcCtD
Vemurafenib—Diarrhoea—Vincristine—peripheral nervous system neoplasm	8.18e-05	0.00101	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	8.06e-05	0.000991	CcSEcCtD
Vemurafenib—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	7.99e-05	0.000982	CcSEcCtD
Vemurafenib—Nausea—Dactinomycin—peripheral nervous system neoplasm	7.95e-05	0.000977	CcSEcCtD
Vemurafenib—Dizziness—Vincristine—peripheral nervous system neoplasm	7.91e-05	0.000971	CcSEcCtD
Vemurafenib—Vomiting—Alitretinoin—peripheral nervous system neoplasm	7.89e-05	0.000969	CcSEcCtD
Vemurafenib—Infestation—Doxorubicin—peripheral nervous system neoplasm	7.88e-05	0.000968	CcSEcCtD
Vemurafenib—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	7.88e-05	0.000968	CcSEcCtD
Vemurafenib—Rash—Alitretinoin—peripheral nervous system neoplasm	7.82e-05	0.000961	CcSEcCtD
Vemurafenib—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	7.82e-05	0.00096	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	7.81e-05	0.000959	CcSEcCtD
Vemurafenib—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	7.79e-05	0.000957	CcSEcCtD
Vemurafenib—Headache—Alitretinoin—peripheral nervous system neoplasm	7.77e-05	0.000955	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	7.72e-05	0.000949	CcSEcCtD
Vemurafenib—Body temperature increased—Etoposide—peripheral nervous system neoplasm	7.66e-05	0.000941	CcSEcCtD
Vemurafenib—Vomiting—Vincristine—peripheral nervous system neoplasm	7.6e-05	0.000934	CcSEcCtD
Vemurafenib—Asthenia—Cisplatin—peripheral nervous system neoplasm	7.59e-05	0.000932	CcSEcCtD
Vemurafenib—Rash—Vincristine—peripheral nervous system neoplasm	7.54e-05	0.000926	CcSEcCtD
Vemurafenib—Dermatitis—Vincristine—peripheral nervous system neoplasm	7.53e-05	0.000925	CcSEcCtD
Vemurafenib—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	7.53e-05	0.000925	CcSEcCtD
Vemurafenib—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	7.51e-05	0.000923	CcSEcCtD
Vemurafenib—Headache—Vincristine—peripheral nervous system neoplasm	7.49e-05	0.00092	CcSEcCtD
Vemurafenib—Nausea—Alitretinoin—peripheral nervous system neoplasm	7.37e-05	0.000905	CcSEcCtD
Vemurafenib—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	7.23e-05	0.000889	CcSEcCtD
Vemurafenib—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	7.23e-05	0.000888	CcSEcCtD
Vemurafenib—Eye disorder—Epirubicin—peripheral nervous system neoplasm	7.14e-05	0.000877	CcSEcCtD
Vemurafenib—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	7.14e-05	0.000877	CcSEcCtD
Vemurafenib—Nausea—Vincristine—peripheral nervous system neoplasm	7.1e-05	0.000873	CcSEcCtD
Vemurafenib—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	7.09e-05	0.000871	CcSEcCtD
Vemurafenib—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	6.97e-05	0.000856	CcSEcCtD
Vemurafenib—Asthenia—Etoposide—peripheral nervous system neoplasm	6.95e-05	0.000854	CcSEcCtD
Vemurafenib—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	6.95e-05	0.000854	CcSEcCtD
Vemurafenib—Angiopathy—Epirubicin—peripheral nervous system neoplasm	6.93e-05	0.000852	CcSEcCtD
Vemurafenib—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	6.89e-05	0.000846	CcSEcCtD
Vemurafenib—Chills—Epirubicin—peripheral nervous system neoplasm	6.86e-05	0.000842	CcSEcCtD
Vemurafenib—Pruritus—Etoposide—peripheral nervous system neoplasm	6.85e-05	0.000842	CcSEcCtD
Vemurafenib—Alopecia—Epirubicin—peripheral nervous system neoplasm	6.75e-05	0.00083	CcSEcCtD
Vemurafenib—Vomiting—Cisplatin—peripheral nervous system neoplasm	6.72e-05	0.000826	CcSEcCtD
Vemurafenib—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	6.69e-05	0.000821	CcSEcCtD
Vemurafenib—Rash—Cisplatin—peripheral nervous system neoplasm	6.67e-05	0.000819	CcSEcCtD
Vemurafenib—Dermatitis—Cisplatin—peripheral nervous system neoplasm	6.66e-05	0.000818	CcSEcCtD
Vemurafenib—Erythema—Epirubicin—peripheral nervous system neoplasm	6.65e-05	0.000817	CcSEcCtD
Vemurafenib—Malnutrition—Epirubicin—peripheral nervous system neoplasm	6.65e-05	0.000817	CcSEcCtD
Vemurafenib—Diarrhoea—Etoposide—peripheral nervous system neoplasm	6.63e-05	0.000814	CcSEcCtD
Vemurafenib—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	6.61e-05	0.000812	CcSEcCtD
Vemurafenib—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	6.56e-05	0.000806	CcSEcCtD
Vemurafenib—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	6.52e-05	0.0008	CcSEcCtD
Vemurafenib—Back pain—Epirubicin—peripheral nervous system neoplasm	6.44e-05	0.000791	CcSEcCtD
Vemurafenib—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	6.42e-05	0.000788	CcSEcCtD
Vemurafenib—Dizziness—Etoposide—peripheral nervous system neoplasm	6.41e-05	0.000787	CcSEcCtD
Vemurafenib—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	6.37e-05	0.000783	CcSEcCtD
Vemurafenib—Chills—Doxorubicin—peripheral nervous system neoplasm	6.35e-05	0.000779	CcSEcCtD
Vemurafenib—Nausea—Cisplatin—peripheral nervous system neoplasm	6.28e-05	0.000771	CcSEcCtD
Vemurafenib—Alopecia—Doxorubicin—peripheral nervous system neoplasm	6.25e-05	0.000768	CcSEcCtD
Vemurafenib—Vomiting—Etoposide—peripheral nervous system neoplasm	6.16e-05	0.000757	CcSEcCtD
Vemurafenib—Erythema—Doxorubicin—peripheral nervous system neoplasm	6.16e-05	0.000756	CcSEcCtD
Vemurafenib—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	6.16e-05	0.000756	CcSEcCtD
Vemurafenib—Rash—Etoposide—peripheral nervous system neoplasm	6.11e-05	0.00075	CcSEcCtD
Vemurafenib—Dermatitis—Etoposide—peripheral nervous system neoplasm	6.1e-05	0.00075	CcSEcCtD
Vemurafenib—Headache—Etoposide—peripheral nervous system neoplasm	6.07e-05	0.000745	CcSEcCtD
Vemurafenib—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	6.03e-05	0.000741	CcSEcCtD
Vemurafenib—Back pain—Doxorubicin—peripheral nervous system neoplasm	5.95e-05	0.000731	CcSEcCtD
Vemurafenib—Cough—Epirubicin—peripheral nervous system neoplasm	5.81e-05	0.000713	CcSEcCtD
Vemurafenib—Nausea—Etoposide—peripheral nervous system neoplasm	5.75e-05	0.000707	CcSEcCtD
Vemurafenib—Arthralgia—Epirubicin—peripheral nervous system neoplasm	5.66e-05	0.000696	CcSEcCtD
Vemurafenib—Myalgia—Epirubicin—peripheral nervous system neoplasm	5.66e-05	0.000696	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	5.63e-05	0.000691	CcSEcCtD
Vemurafenib—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	5.43e-05	0.000667	CcSEcCtD
Vemurafenib—Infection—Epirubicin—peripheral nervous system neoplasm	5.39e-05	0.000663	CcSEcCtD
Vemurafenib—Cough—Doxorubicin—peripheral nervous system neoplasm	5.37e-05	0.00066	CcSEcCtD
Vemurafenib—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	5.32e-05	0.000654	CcSEcCtD
Vemurafenib—Skin disorder—Epirubicin—peripheral nervous system neoplasm	5.27e-05	0.000648	CcSEcCtD
Vemurafenib—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	5.24e-05	0.000644	CcSEcCtD
Vemurafenib—Myalgia—Doxorubicin—peripheral nervous system neoplasm	5.24e-05	0.000644	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	5.2e-05	0.000639	CcSEcCtD
Vemurafenib—Hypotension—Epirubicin—peripheral nervous system neoplasm	5.07e-05	0.000623	CcSEcCtD
Vemurafenib—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	5.02e-05	0.000617	CcSEcCtD
Vemurafenib—Infection—Doxorubicin—peripheral nervous system neoplasm	4.99e-05	0.000613	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	4.95e-05	0.000608	CcSEcCtD
Vemurafenib—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	4.93e-05	0.000605	CcSEcCtD
Vemurafenib—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	4.88e-05	0.000599	CcSEcCtD
Vemurafenib—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	4.72e-05	0.00058	CcSEcCtD
Vemurafenib—Hypotension—Doxorubicin—peripheral nervous system neoplasm	4.69e-05	0.000577	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	4.69e-05	0.000576	CcSEcCtD
Vemurafenib—Fatigue—Epirubicin—peripheral nervous system neoplasm	4.68e-05	0.000575	CcSEcCtD
Vemurafenib—Constipation—Epirubicin—peripheral nervous system neoplasm	4.64e-05	0.00057	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	4.58e-05	0.000562	CcSEcCtD
Vemurafenib—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	4.37e-05	0.000536	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	4.34e-05	0.000533	CcSEcCtD
Vemurafenib—Fatigue—Doxorubicin—peripheral nervous system neoplasm	4.33e-05	0.000532	CcSEcCtD
Vemurafenib—Constipation—Doxorubicin—peripheral nervous system neoplasm	4.3e-05	0.000528	CcSEcCtD
Vemurafenib—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	4.29e-05	0.000527	CcSEcCtD
Vemurafenib—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	4e-05	0.000491	CcSEcCtD
Vemurafenib—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	3.97e-05	0.000488	CcSEcCtD
Vemurafenib—Asthenia—Epirubicin—peripheral nervous system neoplasm	3.9e-05	0.000479	CcSEcCtD
Vemurafenib—Pruritus—Epirubicin—peripheral nervous system neoplasm	3.84e-05	0.000472	CcSEcCtD
Vemurafenib—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	3.72e-05	0.000456	CcSEcCtD
Vemurafenib—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	3.7e-05	0.000455	CcSEcCtD
Vemurafenib—Asthenia—Doxorubicin—peripheral nervous system neoplasm	3.6e-05	0.000443	CcSEcCtD
Vemurafenib—Dizziness—Epirubicin—peripheral nervous system neoplasm	3.59e-05	0.000441	CcSEcCtD
Vemurafenib—Pruritus—Doxorubicin—peripheral nervous system neoplasm	3.55e-05	0.000437	CcSEcCtD
Vemurafenib—Vomiting—Epirubicin—peripheral nervous system neoplasm	3.45e-05	0.000424	CcSEcCtD
Vemurafenib—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	3.44e-05	0.000422	CcSEcCtD
Vemurafenib—Rash—Epirubicin—peripheral nervous system neoplasm	3.42e-05	0.000421	CcSEcCtD
Vemurafenib—Dermatitis—Epirubicin—peripheral nervous system neoplasm	3.42e-05	0.00042	CcSEcCtD
Vemurafenib—Headache—Epirubicin—peripheral nervous system neoplasm	3.4e-05	0.000418	CcSEcCtD
Vemurafenib—Dizziness—Doxorubicin—peripheral nervous system neoplasm	3.32e-05	0.000408	CcSEcCtD
Vemurafenib—Nausea—Epirubicin—peripheral nervous system neoplasm	3.23e-05	0.000396	CcSEcCtD
Vemurafenib—Vomiting—Doxorubicin—peripheral nervous system neoplasm	3.19e-05	0.000392	CcSEcCtD
Vemurafenib—Rash—Doxorubicin—peripheral nervous system neoplasm	3.17e-05	0.000389	CcSEcCtD
Vemurafenib—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	3.16e-05	0.000389	CcSEcCtD
Vemurafenib—Headache—Doxorubicin—peripheral nervous system neoplasm	3.15e-05	0.000387	CcSEcCtD
Vemurafenib—Nausea—Doxorubicin—peripheral nervous system neoplasm	2.98e-05	0.000367	CcSEcCtD
Vemurafenib—RAF1—MAPK Signaling Pathway—MYC—peripheral nervous system neoplasm	2.66e-05	0.00042	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PPIP5K2—peripheral nervous system neoplasm	2.66e-05	0.000419	CbGpPWpGaD
Vemurafenib—ABCG2—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	2.66e-05	0.000419	CbGpPWpGaD
Vemurafenib—RAF1—TGF-beta Signaling Pathway—TP53—peripheral nervous system neoplasm	2.65e-05	0.000418	CbGpPWpGaD
Vemurafenib—RAF1—PDGFR-beta signaling pathway—HRAS—peripheral nervous system neoplasm	2.65e-05	0.000418	CbGpPWpGaD
Vemurafenib—RAF1—VEGFA-VEGFR2 Pathway—AKT1—peripheral nervous system neoplasm	2.65e-05	0.000418	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PPP3R1—peripheral nervous system neoplasm	2.64e-05	0.000417	CbGpPWpGaD
Vemurafenib—BRAF—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	2.63e-05	0.000415	CbGpPWpGaD
Vemurafenib—BRAF—NGF signalling via TRKA from the plasma membrane—HRAS—peripheral nervous system neoplasm	2.57e-05	0.000405	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by FGFR in disease—AKT1—peripheral nervous system neoplasm	2.56e-05	0.000404	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—GNS—peripheral nervous system neoplasm	2.55e-05	0.000402	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by VEGF—AKT1—peripheral nervous system neoplasm	2.5e-05	0.000394	CbGpPWpGaD
Vemurafenib—ALB—Folate Metabolism—TP53—peripheral nervous system neoplasm	2.49e-05	0.000392	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	2.47e-05	0.000389	CbGpPWpGaD
Vemurafenib—BRAF—Disease—SLC2A1—peripheral nervous system neoplasm	2.46e-05	0.000388	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—ERBB2—peripheral nervous system neoplasm	2.46e-05	0.000387	CbGpPWpGaD
Vemurafenib—RAF1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	2.45e-05	0.000387	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—NME1—peripheral nervous system neoplasm	2.44e-05	0.000385	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NTS—peripheral nervous system neoplasm	2.44e-05	0.000385	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PPP3R1—peripheral nervous system neoplasm	2.44e-05	0.000385	CbGpPWpGaD
Vemurafenib—ABCC1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	2.43e-05	0.000383	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—NRAS—peripheral nervous system neoplasm	2.43e-05	0.000383	CbGpPWpGaD
Vemurafenib—RAF1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—peripheral nervous system neoplasm	2.42e-05	0.000382	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PPP3R1—peripheral nervous system neoplasm	2.42e-05	0.000381	CbGpPWpGaD
Vemurafenib—BRAF—Focal Adhesion—AKT1—peripheral nervous system neoplasm	2.42e-05	0.000381	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by SCF-KIT—HRAS—peripheral nervous system neoplasm	2.41e-05	0.000379	CbGpPWpGaD
Vemurafenib—RAF1—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	2.41e-05	0.000379	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	2.4e-05	0.000379	CbGpPWpGaD
Vemurafenib—ABCC1—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	2.38e-05	0.000376	CbGpPWpGaD
Vemurafenib—RAF1—BDNF signaling pathway—HRAS—peripheral nervous system neoplasm	2.37e-05	0.000373	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—COX2—peripheral nervous system neoplasm	2.35e-05	0.000371	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	2.35e-05	0.00037	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CD55—peripheral nervous system neoplasm	2.34e-05	0.000369	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—NCAM1—peripheral nervous system neoplasm	2.34e-05	0.000368	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signaling of activated FGFR—HRAS—peripheral nervous system neoplasm	2.3e-05	0.000363	CbGpPWpGaD
Vemurafenib—BRAF—NGF signalling via TRKA from the plasma membrane—AKT1—peripheral nervous system neoplasm	2.27e-05	0.000358	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB4—HRAS—peripheral nervous system neoplasm	2.27e-05	0.000357	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	2.25e-05	0.000355	CbGpPWpGaD
Vemurafenib—RAF1—TGF-beta Signaling Pathway—AKT1—peripheral nervous system neoplasm	2.24e-05	0.000353	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—CASP3—peripheral nervous system neoplasm	2.23e-05	0.000351	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—ERBB2—peripheral nervous system neoplasm	2.22e-05	0.00035	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	2.22e-05	0.00035	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—TP53—peripheral nervous system neoplasm	2.19e-05	0.000345	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.18e-05	0.000343	CbGpPWpGaD
Vemurafenib—RAF1—Insulin Signaling—HRAS—peripheral nervous system neoplasm	2.17e-05	0.000343	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—MET—peripheral nervous system neoplasm	2.17e-05	0.000342	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signal transduction—HRAS—peripheral nervous system neoplasm	2.16e-05	0.000341	CbGpPWpGaD
Vemurafenib—RAF1—EGF/EGFR Signaling Pathway—HRAS—peripheral nervous system neoplasm	2.15e-05	0.00034	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR—HRAS—peripheral nervous system neoplasm	2.15e-05	0.00034	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB2—HRAS—peripheral nervous system neoplasm	2.14e-05	0.000338	CbGpPWpGaD
Vemurafenib—ABCG2—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	2.14e-05	0.000337	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 signaling—HRAS—peripheral nervous system neoplasm	2.13e-05	0.000336	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by SCF-KIT—AKT1—peripheral nervous system neoplasm	2.12e-05	0.000335	CbGpPWpGaD
Vemurafenib—RAF1—Disease—ENO2—peripheral nervous system neoplasm	2.11e-05	0.000333	CbGpPWpGaD
Vemurafenib—ABCG2—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	2.1e-05	0.000331	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—ENO2—peripheral nervous system neoplasm	2.1e-05	0.00033	CbGpPWpGaD
Vemurafenib—RAF1—BDNF signaling pathway—AKT1—peripheral nervous system neoplasm	2.09e-05	0.000329	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signaling of activated FGFR—AKT1—peripheral nervous system neoplasm	2.03e-05	0.000321	CbGpPWpGaD
Vemurafenib—BRAF—Neuronal System—HRAS—peripheral nervous system neoplasm	2.01e-05	0.000318	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—PTPN11—peripheral nervous system neoplasm	2.01e-05	0.000316	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—HRAS—peripheral nervous system neoplasm	2.01e-05	0.000316	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—HRAS—peripheral nervous system neoplasm	2.01e-05	0.000316	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—HRAS—peripheral nervous system neoplasm	2.01e-05	0.000316	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB4—AKT1—peripheral nervous system neoplasm	2e-05	0.000315	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR—HRAS—peripheral nervous system neoplasm	1.99e-05	0.000313	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—HRAS—peripheral nervous system neoplasm	1.98e-05	0.000311	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	1.97e-05	0.000311	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—HRAS—peripheral nervous system neoplasm	1.97e-05	0.000311	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—PTPN11—peripheral nervous system neoplasm	1.97e-05	0.00031	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—HRAS—peripheral nervous system neoplasm	1.96e-05	0.000309	CbGpPWpGaD
Vemurafenib—RAF1—Insulin Signaling—AKT1—peripheral nervous system neoplasm	1.92e-05	0.000303	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signal transduction—AKT1—peripheral nervous system neoplasm	1.91e-05	0.000301	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR—AKT1—peripheral nervous system neoplasm	1.9e-05	0.0003	CbGpPWpGaD
Vemurafenib—RAF1—EGF/EGFR Signaling Pathway—AKT1—peripheral nervous system neoplasm	1.9e-05	0.0003	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—NRAS—peripheral nervous system neoplasm	1.9e-05	0.0003	CbGpPWpGaD
Vemurafenib—RAF1—Focal Adhesion—HRAS—peripheral nervous system neoplasm	1.9e-05	0.000299	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB2—AKT1—peripheral nervous system neoplasm	1.89e-05	0.000298	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 signaling—AKT1—peripheral nervous system neoplasm	1.88e-05	0.000297	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—IFNB1—peripheral nervous system neoplasm	1.88e-05	0.000297	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—NRAS—peripheral nervous system neoplasm	1.87e-05	0.000295	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	1.86e-05	0.000293	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.86e-05	0.000293	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—VIP—peripheral nervous system neoplasm	1.85e-05	0.000292	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—AKT1—peripheral nervous system neoplasm	1.85e-05	0.000291	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IFNB1—peripheral nervous system neoplasm	1.83e-05	0.000289	CbGpPWpGaD
Vemurafenib—RAF1—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	1.82e-05	0.000287	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	1.81e-05	0.000285	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.8e-05	0.000283	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—HRAS—peripheral nervous system neoplasm	1.78e-05	0.00028	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—PTPN11—peripheral nervous system neoplasm	1.77e-05	0.000279	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—AKT1—peripheral nervous system neoplasm	1.77e-05	0.000279	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—AKT1—peripheral nervous system neoplasm	1.77e-05	0.000279	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—AKT1—peripheral nervous system neoplasm	1.77e-05	0.000279	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR—AKT1—peripheral nervous system neoplasm	1.76e-05	0.000277	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—ENO2—peripheral nervous system neoplasm	1.76e-05	0.000277	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—AKT1—peripheral nervous system neoplasm	1.74e-05	0.000275	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—KNG1—peripheral nervous system neoplasm	1.74e-05	0.000275	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—AKT1—peripheral nervous system neoplasm	1.74e-05	0.000274	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	1.74e-05	0.000274	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—AKT1—peripheral nervous system neoplasm	1.73e-05	0.000273	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	1.72e-05	0.000271	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	1.71e-05	0.000269	CbGpPWpGaD
Vemurafenib—RAF1—Disease—SLC2A1—peripheral nervous system neoplasm	1.7e-05	0.000269	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—PTPN11—peripheral nervous system neoplasm	1.7e-05	0.000268	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—NRAS—peripheral nervous system neoplasm	1.69e-05	0.000267	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—SLC2A1—peripheral nervous system neoplasm	1.69e-05	0.000266	CbGpPWpGaD
Vemurafenib—RAF1—Focal Adhesion—AKT1—peripheral nervous system neoplasm	1.67e-05	0.000264	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	1.67e-05	0.000263	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	1.64e-05	0.000259	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.63e-05	0.000256	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.59e-05	0.00025	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—ERBB2—peripheral nervous system neoplasm	1.59e-05	0.00025	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GNS—peripheral nervous system neoplasm	1.57e-05	0.000248	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—AKT1—peripheral nervous system neoplasm	1.57e-05	0.000247	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—ENO2—peripheral nervous system neoplasm	1.54e-05	0.000243	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—GNAS—peripheral nervous system neoplasm	1.52e-05	0.00024	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.52e-05	0.00024	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.51e-05	0.000238	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—NME1—peripheral nervous system neoplasm	1.51e-05	0.000238	CbGpPWpGaD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	1.48e-05	0.000234	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—BCHE—peripheral nervous system neoplasm	1.48e-05	0.000234	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—HGF—peripheral nervous system neoplasm	1.45e-05	0.000229	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—COX2—peripheral nervous system neoplasm	1.45e-05	0.000229	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.41e-05	0.000223	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HGF—peripheral nervous system neoplasm	1.41e-05	0.000223	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—ERBB2—peripheral nervous system neoplasm	1.4e-05	0.000221	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—TH—peripheral nervous system neoplasm	1.39e-05	0.00022	CbGpPWpGaD
Vemurafenib—RAF1—Neuronal System—HRAS—peripheral nervous system neoplasm	1.39e-05	0.00022	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—HRAS—peripheral nervous system neoplasm	1.39e-05	0.000219	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.39e-05	0.000219	CbGpPWpGaD
Vemurafenib—BRAF—Disease—PTPN11—peripheral nervous system neoplasm	1.38e-05	0.000217	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—HRAS—peripheral nervous system neoplasm	1.37e-05	0.000215	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—ERBB2—peripheral nervous system neoplasm	1.34e-05	0.000212	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	1.32e-05	0.000208	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—BCHE—peripheral nervous system neoplasm	1.3e-05	0.000206	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GNS—peripheral nervous system neoplasm	1.3e-05	0.000205	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	1.29e-05	0.000204	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.28e-05	0.000202	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	1.26e-05	0.000199	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—NME1—peripheral nervous system neoplasm	1.25e-05	0.000196	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.24e-05	0.000196	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—HRAS—peripheral nervous system neoplasm	1.24e-05	0.000195	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—TH—peripheral nervous system neoplasm	1.23e-05	0.000193	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—AKT1—peripheral nervous system neoplasm	1.21e-05	0.00019	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—NRAS—peripheral nervous system neoplasm	1.21e-05	0.00019	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—COX2—peripheral nervous system neoplasm	1.2e-05	0.000189	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—NRAS—peripheral nervous system neoplasm	1.18e-05	0.000187	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.17e-05	0.000185	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—GNAS—peripheral nervous system neoplasm	1.14e-05	0.000179	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.13e-05	0.000178	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—ABCB1—peripheral nervous system neoplasm	1.12e-05	0.000176	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GNS—peripheral nervous system neoplasm	1.1e-05	0.000173	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.1e-05	0.000173	CbGpPWpGaD
Vemurafenib—BRAF—Disease—ERBB2—peripheral nervous system neoplasm	1.09e-05	0.000172	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—NRAS—peripheral nervous system neoplasm	1.07e-05	0.000168	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—PTPN11—peripheral nervous system neoplasm	1.06e-05	0.000167	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NME1—peripheral nervous system neoplasm	1.05e-05	0.000166	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.05e-05	0.000165	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PTPN11—peripheral nervous system neoplasm	1.03e-05	0.000163	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	1.02e-05	0.000161	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—COX2—peripheral nervous system neoplasm	1.02e-05	0.00016	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—GNAS—peripheral nervous system neoplasm	1e-05	0.000158	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—ABCB1—peripheral nervous system neoplasm	9.83e-06	0.000155	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	9.65e-06	0.000152	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	9.6e-06	0.000151	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ENO2—peripheral nervous system neoplasm	9.53e-06	0.00015	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PTPN11—peripheral nervous system neoplasm	9.53e-06	0.00015	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PTPN11—peripheral nervous system neoplasm	9.45e-06	0.000149	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—TP53—peripheral nervous system neoplasm	9.05e-06	0.000143	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—HRAS—peripheral nervous system neoplasm	8.83e-06	0.000139	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—HRAS—peripheral nervous system neoplasm	8.66e-06	0.000137	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	8.49e-06	0.000134	CbGpPWpGaD
Vemurafenib—BRAF—Disease—NRAS—peripheral nervous system neoplasm	8.28e-06	0.000131	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—ERBB2—peripheral nervous system neoplasm	8.16e-06	0.000129	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	8.14e-06	0.000128	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—BCHE—peripheral nervous system neoplasm	8.05e-06	0.000127	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	7.98e-06	0.000126	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ENO2—peripheral nervous system neoplasm	7.87e-06	0.000124	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	7.84e-06	0.000124	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—HRAS—peripheral nervous system neoplasm	7.79e-06	0.000123	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—AKT1—peripheral nervous system neoplasm	7.79e-06	0.000123	CbGpPWpGaD
Vemurafenib—BRAF—Disease—MYC—peripheral nervous system neoplasm	7.71e-06	0.000122	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—SLC2A1—peripheral nervous system neoplasm	7.68e-06	0.000121	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—AKT1—peripheral nervous system neoplasm	7.65e-06	0.000121	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	7.62e-06	0.00012	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—TH—peripheral nervous system neoplasm	7.57e-06	0.000119	CbGpPWpGaD
Vemurafenib—RAF1—Disease—ERBB2—peripheral nervous system neoplasm	7.53e-06	0.000119	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	7.49e-06	0.000118	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—ERBB2—peripheral nervous system neoplasm	7.47e-06	0.000118	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CASP3—peripheral nervous system neoplasm	6.92e-06	0.000109	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—AKT1—peripheral nervous system neoplasm	6.88e-06	0.000109	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	6.79e-06	0.000107	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.67e-06	0.000105	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ENO2—peripheral nervous system neoplasm	6.67e-06	0.000105	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—BCHE—peripheral nervous system neoplasm	6.65e-06	0.000105	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	6.61e-06	0.000104	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—NRAS—peripheral nervous system neoplasm	6.37e-06	0.0001	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.34e-06	0.0001	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—TH—peripheral nervous system neoplasm	6.25e-06	9.86e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—NRAS—peripheral nervous system neoplasm	6.21e-06	9.78e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GNAS—peripheral nervous system neoplasm	6.18e-06	9.74e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ABCB1—peripheral nervous system neoplasm	6.06e-06	9.56e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—HRAS—peripheral nervous system neoplasm	6.06e-06	9.55e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.8e-06	9.14e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—NRAS—peripheral nervous system neoplasm	5.73e-06	9.03e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—NRAS—peripheral nervous system neoplasm	5.68e-06	8.95e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—BCHE—peripheral nervous system neoplasm	5.63e-06	8.88e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.4e-06	8.52e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.37e-06	8.47e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—AKT1—peripheral nervous system neoplasm	5.35e-06	8.43e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MYC—peripheral nervous system neoplasm	5.34e-06	8.41e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—TH—peripheral nervous system neoplasm	5.3e-06	8.35e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MYC—peripheral nervous system neoplasm	5.29e-06	8.34e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.27e-06	8.31e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	5.14e-06	8.11e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GNAS—peripheral nervous system neoplasm	5.1e-06	8.05e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ABCB1—peripheral nervous system neoplasm	5.01e-06	7.89e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	4.97e-06	7.83e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TP53—peripheral nervous system neoplasm	4.87e-06	7.68e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.79e-06	7.55e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—HRAS—peripheral nervous system neoplasm	4.66e-06	7.35e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HRAS—peripheral nervous system neoplasm	4.54e-06	7.16e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.44e-06	6.99e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.39e-06	6.92e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	4.35e-06	6.85e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GNAS—peripheral nervous system neoplasm	4.32e-06	6.82e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.24e-06	6.69e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ABCB1—peripheral nervous system neoplasm	4.24e-06	6.69e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—HRAS—peripheral nervous system neoplasm	4.19e-06	6.61e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—HRAS—peripheral nervous system neoplasm	4.16e-06	6.55e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	4.15e-06	6.54e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—AKT1—peripheral nervous system neoplasm	4.11e-06	6.49e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	4.09e-06	6.44e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.01e-06	6.33e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—AKT1—peripheral nervous system neoplasm	4.01e-06	6.32e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.75e-06	5.91e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.74e-06	5.89e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—AKT1—peripheral nervous system neoplasm	3.7e-06	5.84e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—AKT1—peripheral nervous system neoplasm	3.67e-06	5.78e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	3.34e-06	5.26e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	3.27e-06	5.16e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—AKT1—peripheral nervous system neoplasm	3.07e-06	4.84e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.07e-06	4.84e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.94e-06	4.63e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—AKT1—peripheral nervous system neoplasm	2.7e-06	4.26e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.59e-06	4.09e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—AKT1—peripheral nervous system neoplasm	1.67e-06	2.63e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—AKT1—peripheral nervous system neoplasm	1.38e-06	2.17e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—AKT1—peripheral nervous system neoplasm	1.17e-06	1.84e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	9.01e-07	1.42e-05	CbGpPWpGaD
